Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$20.35
-0.02-0.10%
At close: -
$20.35
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Celldex Therapeutics Analyst Ratings and Price Targets | NASDAQ:CLDX | Benzinga
Celldex Therapeutics Inc has a consensus price target of $57 based on the ratings of 13 analysts. The high is $90 issued by Guggenheim on February 27, 2024. The low is $31 issued by Goldman Sachs on May 9, 2025. The 3 most-recent analyst ratings were released by UBS, Goldman Sachs, and Morgan Stanley on May 9, 2025, respectively. With an average price target of $37.33 between UBS, Goldman Sachs, and Morgan Stanley, there's an implied 83.46% upside for Celldex Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
UBS
Goldman Sachs
Morgan Stanley
HC Wainwright & Co.
Canaccord Genuity
1calculated from analyst ratings
Analyst Ratings for Celldex Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/09/2025 | Buy Now | 86.73% | UBS | Trung Huynh66% | $44 → $38 | Maintains | Buy | Get Alert |
| 05/09/2025 | Buy Now | 52.33% | Goldman Sachs | Richard Law46% | $36 → $31 | Maintains | Neutral | Get Alert |
| 05/09/2025 | Buy Now | 111.3% | Morgan Stanley | Judah Frommer65% | $46 → $43 | Maintains | Overweight | Get Alert |
| 05/09/2025 | Buy Now | 145.7% | HC Wainwright & Co. | Joseph Pantginis45% | $80 → $50 | Maintains | Buy | Get Alert |
| 05/06/2025 | Buy Now | 293.12% | HC Wainwright & Co. | Joseph Pantginis45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 04/28/2025 | Buy Now | 214.5% | Canaccord Genuity | Edward Nash66% | → $64 | Initiates | → Buy | Get Alert |
| 03/20/2025 | Buy Now | 126.04% | Morgan Stanley | Judah Frommer65% | → $46 | Initiates | → Overweight | Get Alert |
| 03/03/2025 | Buy Now | 76.9% | Goldman Sachs | Richard Law46% | $42 → $36 | Maintains | Neutral | Get Alert |
| 03/03/2025 | Buy Now | 293.12% | HC Wainwright & Co. | Joseph Pantginis45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2025 | Buy Now | 293.12% | HC Wainwright & Co. | Joseph Pantginis45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 02/13/2025 | Buy Now | 116.22% | UBS | Trung Huynh66% | → $44 | Initiates | → Buy | Get Alert |
| 01/29/2025 | Buy Now | 229.24% | Cantor Fitzgerald | Kristen Kluska71% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 01/02/2025 | Buy Now | 229.24% | Cantor Fitzgerald | Kristen Kluska71% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 12/20/2024 | Buy Now | 293.12% | HC Wainwright & Co. | Joseph Pantginis45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 12/19/2024 | Buy Now | 293.12% | HC Wainwright & Co. | Joseph Pantginis45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2024 | Buy Now | 293.12% | HC Wainwright & Co. | Joseph Pantginis45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2024 | Buy Now | 293.12% | HC Wainwright & Co. | Joseph Pantginis45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 10/28/2024 | Buy Now | 293.12% | HC Wainwright & Co. | Joseph Pantginis45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 10/07/2024 | Buy Now | 243.98% | Citigroup | David Lebowitz53% | → $70 | Initiates | → Buy | Get Alert |
| 09/30/2024 | Buy Now | 121.13% | Goldman Sachs | Richard Law46% | → $45 | Initiates | → Neutral | Get Alert |
| 09/27/2024 | Buy Now | — | Wolfe Research | Andy Chen41% | — | Downgrade | Outperform → Peer Perform | Get Alert |
| 09/26/2024 | Buy Now | 293.12% | HC Wainwright & Co. | Joseph Pantginis45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 09/25/2024 | Buy Now | 150.61% | Wolfe Research | Andy Chen41% | $51 → $51 | Reiterates | Outperform → Outperform | Get Alert |
| 09/20/2024 | Buy Now | 229.24% | Cantor Fitzgerald | Kristen Kluska71% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 09/18/2024 | Buy Now | 229.24% | Cantor Fitzgerald | Kristen Kluska71% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 09/16/2024 | Buy Now | 229.24% | Cantor Fitzgerald | Kristen Kluska71% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 09/09/2024 | Buy Now | 229.24% | Cantor Fitzgerald | Kristen Kluska71% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 08/12/2024 | Buy Now | 81.82% | Wells Fargo | Derek Archila58% | $35 → $37 | Maintains | Equal-Weight | Get Alert |
| 08/12/2024 | Buy Now | 293.12% | HC Wainwright & Co. | Joseph Pantginis45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 07/30/2024 | Buy Now | 229.24% | Cantor Fitzgerald | Kristen Kluska71% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 07/30/2024 | Buy Now | 293.12% | HC Wainwright & Co. | Joseph Pantginis45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 07/16/2024 | Buy Now | 293.12% | HC Wainwright & Co. | Joseph Pantginis45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 06/18/2024 | Buy Now | 229.24% | Cantor Fitzgerald | Kristen Kluska71% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 06/11/2024 | Buy Now | — | Wolfe Research | Andy Chen41% | — | Initiates | → Outperform | Get Alert |
| 06/03/2024 | Buy Now | 293.12% | HC Wainwright & Co. | Joseph Pantginis45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2024 | Buy Now | 293.12% | HC Wainwright & Co. | Joseph Pantginis45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | 293.12% | HC Wainwright & Co. | Joseph Pantginis45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 04/17/2024 | Buy Now | 293.12% | HC Wainwright & Co. | Joseph Pantginis45% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 03/22/2024 | Buy Now | 229.24% | Cantor Fitzgerald | Kristen Kluska71% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 02/27/2024 | Buy Now | 342.26% | Guggenheim | Yatin Suneja51% | $72 → $90 | Maintains | Buy | Get Alert |
| 12/20/2023 | Buy Now | — | TD Cowen | Yaron Werber35% | — | Initiates | → Outperform | Get Alert |
| 11/10/2023 | Buy Now | 32.68% | Wells Fargo | Derek Archila58% | → $27 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 11/06/2023 | Buy Now | 293.12% | HC Wainwright & Co. | Joseph Pantginis45% | $73 → $80 | Maintains | Buy | Get Alert |
| 11/03/2023 | Buy Now | 155.53% | Cantor Fitzgerald | Kristen Kluska71% | $54 → $52 | Maintains | Overweight | Get Alert |
| 10/12/2023 | Buy Now | 165.36% | Cantor Fitzgerald | Kristen Kluska71% | → $54 | Reiterates | Overweight → Overweight | Get Alert |
| 09/27/2023 | Buy Now | 165.36% | Cantor Fitzgerald | Kristen Kluska71% | → $54 | Reiterates | Overweight → Overweight | Get Alert |
| 08/22/2023 | Buy Now | 3.19% | Wells Fargo | Derek Archila58% | → $21 | Initiates | → Underweight | Get Alert |
| 08/16/2023 | Buy Now | 165.36% | Cantor Fitzgerald | Kristen Kluska71% | → $54 | Reiterates | Overweight → Overweight | Get Alert |
| 08/10/2023 | Buy Now | 258.72% | HC Wainwright & Co. | Joseph Pantginis45% | → $73 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 258.72% | HC Wainwright & Co. | Joseph Pantginis45% | → $73 | Reiterates | Buy → Buy | Get Alert |
| 06/12/2023 | Buy Now | 258.72% | HC Wainwright & Co. | Joseph Pantginis45% | → $73 | Reiterates | Buy → Buy | Get Alert |
| 05/31/2023 | Buy Now | 258.72% | HC Wainwright & Co. | Joseph Pantginis45% | → $73 | Reiterates | → Buy | Get Alert |
| 05/05/2023 | Buy Now | 165.36% | Cantor Fitzgerald | Kristen Kluska71% | $55 → $54 | Maintains | Overweight | Get Alert |
| 05/05/2023 | Buy Now | 258.72% | HC Wainwright & Co. | Joseph Pantginis45% | → $73 | Reiterates | → Buy | Get Alert |
| 03/22/2023 | Buy Now | 258.72% | HC Wainwright & Co. | Joseph Pantginis45% | → $73 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | 258.72% | HC Wainwright & Co. | Joseph Pantginis45% | → $73 | Reiterates | → Buy | Get Alert |
| 02/27/2023 | Buy Now | 258.72% | HC Wainwright & Co. | Joseph Pantginis45% | → $73 | Reiterates | → Buy | Get Alert |
| 11/11/2022 | Buy Now | 209.58% | Guggenheim | Yatin Suneja51% | $68 → $63 | Maintains | Buy | Get Alert |
| 08/09/2022 | Buy Now | 214.5% | SVB Leerink | Thomas Smith33% | $68 → $64 | Maintains | Outperform | Get Alert |
| 07/01/2022 | Buy Now | 258.72% | HC Wainwright & Co. | Joseph Hafling29% | $60 → $73 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Celldex Therapeutics (CLDX) stock?
The latest price target for Celldex Therapeutics (NASDAQ:CLDX) was reported by UBS on May 9, 2025. The analyst firm set a price target for $38.00 expecting CLDX to rise to within 12 months (a possible 86.73% upside). 35 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Celldex Therapeutics (CLDX)?
The latest analyst rating for Celldex Therapeutics (NASDAQ:CLDX) was provided by UBS, and Celldex Therapeutics maintained their buy rating.
When was the last upgrade for Celldex Therapeutics (CLDX)?
The last upgrade for Celldex Therapeutics Inc happened on November 10, 2023 when Wells Fargo raised their price target to $27. Wells Fargo previously had an underweight for Celldex Therapeutics Inc.
When was the last downgrade for Celldex Therapeutics (CLDX)?
The last downgrade for Celldex Therapeutics Inc happened on September 27, 2024 when Wolfe Research changed their price target from N/A to N/A for Celldex Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Celldex Therapeutics (CLDX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Celldex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Celldex Therapeutics was filed on May 9, 2025 so you should expect the next rating to be made available sometime around May 9, 2026.
Is the Analyst Rating Celldex Therapeutics (CLDX) correct?
While ratings are subjective and will change, the latest Celldex Therapeutics (CLDX) rating was a maintained with a price target of $44.00 to $38.00. The current price Celldex Therapeutics (CLDX) is trading at is $20.35, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
